[HTML][HTML] Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

YX Ning, X Luo, M Xu, X Feng, J Wang - Oncotarget, 2017 - ncbi.nlm.nih.gov
Abstract c-Myc is a key oncogenic transcription factor that participates in tumor
pathogenesis. In this study, we found that levels of c-Myc mRNA and protein were higher in …

[HTML][HTML] Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

YX Ning, X Luo, M Xu, X Feng, J Wang - Oncotarget, 2017 - oncotarget.com
Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc |
Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home Editorial Board Submission …

Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

YX Ning, X Luo, M Xu, X Feng, J Wang - Oncotarget, 2017 - pubmed.ncbi.nlm.nih.gov
c-Myc is a key oncogenic transcription factor that participates in tumor pathogenesis. In this
study, we found that levels of c-Myc mRNA and protein were higher in early ovarian cancer …

Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc.

YX Ning, X Luo, M Xu, X Feng, J Wang - Oncotarget, 2017 - europepmc.org
Abstract c-Myc is a key oncogenic transcription factor that participates in tumor
pathogenesis. In this study, we found that levels of c-Myc mRNA and protein were higher in …

Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc.

YX Ning, X Luo, M Xu, X Feng, J Wang - Oncotarget, 2017 - europepmc.org
Abstract c-Myc is a key oncogenic transcription factor that participates in tumor
pathogenesis. In this study, we found that levels of c-Myc mRNA and protein were higher in …

Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

YX Ning, X Luo, M Xu, X Feng, J Wang - Oncotarget, 2017 - oncotarget.com
Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc |
Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home Editorial Board Submission …